2021
Chapter 15 Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development
Huang Y, Jia H, Bao W. Chapter 15 Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development. 2021, 367-412. DOI: 10.1016/b978-0-12-816475-4.00013-6.Peer-Reviewed Original ResearchAlzheimer's diseasePathologic featuresApplication of PETDrug developmentSynaptic vesicle protein 2ADifferent pathologic featuresFeatures of neurodegenerationCentral nervous systemAD drug developmentPositron emission tomographyNeuroinflammation biomarkersCholinergic systemΒ-amyloidNervous systemTau proteinEmission tomographyAD researchDiseaseProtein 2AInvestigation of diseasesQuantitative imaging techniquesTomographyImaging techniquesAgentsPET
2020
PET Imaging of Synaptic Vesicle Protein 2A
Finnema S, Li S, Cai Z, Naganawa M, Chen M, Matuskey D, Nabulsi N, Esterlis I, Holmes S, Radhakrishnan R, Toyonaga T, Huang Y, Carson R. PET Imaging of Synaptic Vesicle Protein 2A. 2020, 993-1019. DOI: 10.1007/978-3-030-53176-8_29.ChaptersSynaptic vesicle protein 2APositron emission tomographyAntiepileptic drug levetiracetamInitial PET studiesPET imagingPET studiesSynaptic densityDrug levetiracetamHigh-affinity SV2A ligandsBrain regionsSynaptic density lossNeuropathological diseasesDisease-modifying therapiesLarge patient cohortMajor depressive disorderProtein 2APET imaging resultsPosttraumatic stress disorderPatient groupPatient cohortDepressive disorderClinical valueParkinson's diseaseEfficacy assessmentSynaptic vesicle proteins